Forteo denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for forteo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Forteo as Duplicate Therapy

Cigna's duplicate-therapy denial means the plan determined that another osteoporosis medication already on your profile covers the same clinical purpose as teriparatide (Forteo). This most commonly happens when a bisphosphonate, denosumab, or another bone-building agent appears active in your pharmacy or medical claims — even if that prior drug was stopped, was inadequate, or is mechanistically different.

This denial is frequently incorrect and highly worth appealing. Teriparatide is an anabolic (bone-forming) agent with a distinct mechanism from antiresorptive drugs. A prescriber can document why the prior or concurrent agent does not duplicate — and cannot substitute for — what teriparatide provides for your specific case.

## Federal Appeal Framework

You have layered protections regardless of whether your plan is employer-sponsored or purchased through the marketplace:

• Internal appeal: File within the timeframe stated in your denial letter (typically 180 days). Cigna must respond within 30 days for non-urgent requests.
• External review (ACA §2719 / ERISA §503): If the internal appeal is denied, you have the right to an independent external review by an accredited Independent Review Organization (IRO). The window to request external review is generally 4 months from the internal denial. Expedited review (72-hour turnaround) is available when a standard timeline would seriously jeopardize your health.

## Documentation to Gather

1. Diagnosis confirmation: Current bone density (DXA) report, fracture history, and the treating physician's documented clinical severity assessment. 2. Prior-treatment history: A complete, dated list of every osteoporosis agent you have used — what was prescribed, when, the dose achieved, how long it was taken, and exactly why it was stopped (intolerance, inadequate response, contraindication per your physician). 3. Mechanistic distinction letter: A prescriber letter explaining that teriparatide's anabolic mechanism is not duplicated by any antiresorptive agent currently or previously on your record, and why your clinical situation requires it. 4. Applicable guidelines: A reference to the relevant guideline organization (e.g., the American Association of Clinical Endocrinologists / American College of Endocrinology, or applicable Endocrine Society guidelines) supporting anabolic therapy in your clinical setting.

## Criteria-Mapping Structure

Pull Cigna's published medical coverage policy for teriparatide and the FDA-approved prescribing label. List every requirement Cigna states. For each one, write the exact chart fact that satisfies it. Explicitly address any item that could be read as a duplication exclusion — document with specificity why your prior agents do not constitute therapeutic duplication of an anabolic mechanism. Submit the mapping as a cover sheet so the reviewer does not have to search.